Yonglong Xiao

1.4k total citations
74 papers, 979 citations indexed

About

Yonglong Xiao is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Physiology. According to data from OpenAlex, Yonglong Xiao has authored 74 papers receiving a total of 979 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pulmonary and Respiratory Medicine, 17 papers in Epidemiology and 14 papers in Physiology. Recurrent topics in Yonglong Xiao's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (38 papers), Medical Imaging and Pathology Studies (16 papers) and Neonatal Respiratory Health Research (11 papers). Yonglong Xiao is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (38 papers), Medical Imaging and Pathology Studies (16 papers) and Neonatal Respiratory Health Research (11 papers). Yonglong Xiao collaborates with scholars based in China, United States and Switzerland. Yonglong Xiao's co-authors include Hourong Cai, Liyun Miao, Mengshu Cao, Yuying Qiu, Hui Li, Deping Zhang, Jingjing Ding, Yan Wu, Tao Bian and Fanqing Meng and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and Journal of Controlled Release.

In The Last Decade

Yonglong Xiao

68 papers receiving 964 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Yonglong Xiao 400 281 227 206 145 74 979
Louis J. Vuga 900 2.3× 277 1.0× 104 0.5× 100 0.5× 226 1.6× 14 1.2k
Mark C. Blaser 382 1.0× 312 1.1× 147 0.6× 206 1.0× 52 0.4× 33 1.3k
Carolina García de Alba 773 1.9× 322 1.1× 66 0.3× 109 0.5× 167 1.2× 18 1.3k
Shunsuke Minagawa 762 1.9× 487 1.7× 156 0.7× 290 1.4× 386 2.7× 48 1.5k
Elena Tagliabue 180 0.5× 174 0.6× 144 0.6× 117 0.6× 80 0.6× 48 866
Xiang Wei 304 0.8× 378 1.3× 130 0.6× 116 0.6× 43 0.3× 72 1.0k
Mareike Lehmann 879 2.2× 480 1.7× 93 0.4× 89 0.4× 200 1.4× 47 1.5k
Júlio Flávio Meirelles Marchini 217 0.5× 430 1.5× 240 1.1× 115 0.6× 47 0.3× 45 1.1k
José Cisneros 1.3k 3.3× 445 1.6× 202 0.9× 127 0.6× 333 2.3× 41 1.9k
Hee Kyung Kim 226 0.6× 293 1.0× 143 0.6× 96 0.5× 58 0.4× 55 892

Countries citing papers authored by Yonglong Xiao

Since Specialization
Citations

This map shows the geographic impact of Yonglong Xiao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yonglong Xiao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yonglong Xiao more than expected).

Fields of papers citing papers by Yonglong Xiao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yonglong Xiao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yonglong Xiao. The network helps show where Yonglong Xiao may publish in the future.

Co-authorship network of co-authors of Yonglong Xiao

This figure shows the co-authorship network connecting the top 25 collaborators of Yonglong Xiao. A scholar is included among the top collaborators of Yonglong Xiao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yonglong Xiao. Yonglong Xiao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gui, Xianhua, Xiaohua Qiu, Yujuan Gao, et al.. (2025). Chlamydia psittaci infection-associated acute fibrinous and organizing pneumonitis: A case report. IDCases. 40. e02217–e02217.
3.
Xu, Xuefeng, et al.. (2025). Transbronchial lung cryobiopsy for diagnosing interstitial lung disease: a cross-sectional, comparative study. European journal of medical research. 30(1). 171–171.
4.
Huang, Xinmei, Xin Yan, Qiuyan Huang, et al.. (2025). Integrin/CD44-targeted liposomes remodel the pulmonary microenvironment to alleviate acute exacerbation of pulmonary fibrosis. Journal of Controlled Release. 389. 114427–114427.
5.
Gui, Xianhua, Wang‐Zhong Li, Tingting Zhao, et al.. (2024). Pretreatment mortality risk prediction model in patients with polymyositis/dermatomyositis-associated interstitial lung disease. RMD Open. 10(2). e003850–e003850. 1 indexed citations
6.
Huang, Jiannan, Ai Ge, Hai‐Wen Lu, et al.. (2023). Updated severity and prognosis score of pulmonary alveolar proteinosis: A multi-center cohort study in China. Frontiers in Medicine. 10. 1058001–1058001. 3 indexed citations
7.
Huang, Xinmei, Mengshu Cao, & Yonglong Xiao. (2023). Alveolar macrophages in pulmonary alveolar proteinosis: origin, function, and therapeutic strategies. Frontiers in Immunology. 14. 1195988–1195988. 13 indexed citations
8.
Liang, Yi, Tong Ji, Qingqing Xu, et al.. (2023). Elevated serum mitochondrial DNA levels were associated with the progression and mortality in idiopathic pulmonary fibrosis. International Immunopharmacology. 123. 110754–110754. 3 indexed citations
9.
Gui, Xianhua, et al.. (2022). Assessment of Statin Treatment for Pulmonary Alveolar Proteinosis without Hypercholesterolemia: A 12‐Month Prospective, Longitudinal, and Observational Study. BioMed Research International. 2022(1). 1589660–1589660. 12 indexed citations
10.
Gui, Xianhua, Hui Ding, Tingting Zhao, et al.. (2022). Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease. Lara D. Veeken. 61(11). 4570–4578. 44 indexed citations
11.
Xu, Qingqing, Xiaoqin Liu, Yin Liu, et al.. (2022). Increased serum levels of sCD40L were associated with rapidly progressive interstitial lung disease in idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology. 41(2). 267–274. 3 indexed citations
12.
Chen, Hao, Yin Liu, Mei Huang, et al.. (2022). An observational study of clinical recurrence in patients with interstitial lung disease related to the antisynthetase syndrome. Clinical Rheumatology. 42(3). 711–720. 5 indexed citations
13.
14.
Chen, Ling, Yan Li, Xiaoyan Xin, et al.. (2021). Long-term follow-up and successful treatment of pulmonary alveolar proteinosis without hypercholesterolemia with statin therapy: a case report. Journal of International Medical Research. 49(4). 3619070974–3619070974. 8 indexed citations
15.
Liu, Yin, et al.. (2020). Correlation between serum bilirubin levels and the severity as well as the prognosis of idiopathic pulmonary fibrosis. Chronic Respiratory Disease. 17. 405200108–405200108. 1 indexed citations
16.
Qiu, Xiaohua, et al.. (2019). Valuable Serum Markers in Pulmonary Alveolar Proteinosis. Disease Markers. 2019. 1–6. 5 indexed citations
17.
Xiao, Yonglong, Xiaohua Qiu, Yan Li, et al.. (2019). Prognostic effects of clinical and CT imaging features on critically ill patients with interstitial lung disease hospitalized in respiratory intensive care unit. Scientific Reports. 9(1). 17190–17190. 2 indexed citations
18.
Zhou, Fuling, Xiqian Xing, Xiudi Han, et al.. (2018). [Clinical characteristics and prognosis of long-term glucocorticoid users with community-acquired pneumonia].. PubMed. 98(10). 738–743. 2 indexed citations
19.
Li, Yan, Liyun Miao, Min Yu, et al.. (2017). α1-antitrypsin promotes lung adenocarcinoma metastasis through upregulating fibronectin expression. International Journal of Oncology. 50(6). 1955–1964. 26 indexed citations
20.
Liu, Yin, et al.. (2016). Pulmonary infiltration with eosinophilia complicated with mucosa-associated lymphoid tissue lymphoma: A case report. Oncology Letters. 12(3). 1818–1820. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Louis J. Vuga Breakdown of academic impact, for papers by Mark C. Blaser Breakdown of academic impact, for papers by Carolina García de Alba Breakdown of academic impact, for papers by Shunsuke Minagawa Breakdown of academic impact, for papers by Elena Tagliabue Breakdown of academic impact, for papers by Xiang Wei Breakdown of academic impact, for papers by Mareike Lehmann Breakdown of academic impact, for papers by Júlio Flávio Meirelles Marchini Breakdown of academic impact, for papers by José Cisneros Breakdown of academic impact, for papers by Hee Kyung Kim
Rankless by CCL
2026